OptimizeRx Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; unaudited. OptimizeRx is a digital health technology company connecting life sciences organizations, healthcare providers and patients through a point-of-care network. The company reported that its platform reaches more than 60% of U.S. healthcare providers.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change / context |
|---|---|---|---|
| Revenue | $13.73 million | $11.23 million | Up 22%; growth came from messaging and access solutions. |
| Gross profit / margin | $8.10 million / 59% | $6.12 million / 55% | Margin improvement attributed to solution and delivery-channel mix and higher-margin program-design services. |
| Operating expenses | $11.86 million | $6.76 million | Up about 75%, reflecting hiring, infrastructure investment and higher stock-based compensation. |
| Net loss / diluted loss per share | $3.76 million / $0.21 | $0.64 million / $0.04 | Loss widened substantially; diluted shares equal basic shares because potential shares were anti-dilutive. |
| Cash from operations | $4.08 million | $1.67 million | Improved, with receivables collections and noncash expenses offsetting the net loss. |
| Cash and cash equivalents | $88.95 million | $84.68 million at Dec. 31, 2021 | Quarter-end balance. |
| Liquidity | Current assets $112.70 million; current liabilities $6.88 million | — | Working capital about $105.8 million; current ratio about 16:1. |
| Debt and lease obligations | No debt reported; lease liabilities $0.30 million | — | Lease liabilities comprise $0.09 million current and $0.21 million noncurrent. |
Changes and operating indicators
- Stock-based compensation rose to $3.17 million from $0.71 million, including $1.50 million of expense related to market-based awards. The filing reports $29.57 million of remaining expense for unvested options and restricted stock units combined.
- The company added 20 net employees over the prior 12 months and cited increased investment in product development, sales, IT and technology infrastructure.
- For the rolling 12 months ended March 31, revenue per top-20 pharmaceutical manufacturer increased to $2.55 million from $2.12 million; 95% of those manufacturers were customers versus 85%. Top-20 pharma accounted for 76% of revenue versus 77%.
- Net revenue retention was 124%, down from 161%; management attributed the prior-year comparison partly to pandemic-related shifts in customer spending. Revenue per average full-time employee increased to $733,275 from $634,571.
- Q1 2021 included $70.67 million of net proceeds from a public stock offering; there was no comparable offering in Q1 2022. Q1 2022 financing cash inflow was $0.26 million from option exercises.
Outlook, risks and other notable items
- Management expects revenue to continue growing during 2022, citing new clients and investments made in pharmaceutical brands, distribution and messaging. It expects gross margin to remain relatively constant, operating expenses to increase in Q2 and rise more slowly during the rest of the year. No numerical full-year guidance was provided.
- Management believes current cash and operating cash generation will fund operations and planned growth for at least 12 months; it may seek financing for acquisitions, strategic relationships, capital expenditures or working capital.
- In April 2022, after quarter-end, OptimizeRx completed its acquisition of substantially all EvinceMed assets for $2 million cash and 240,741 shares. The filing values the shares at approximately $9.37 million and says purchase-price allocation was not yet available.
- Management said COVID-19 had no material net impact on Q1 financial statements but noted that future effects remain uncertain. Cited risks include customer concentration, healthcare regulation, competition, scaling and integration of acquisitions, cybersecurity, network reliability and international operations.
- No material pending litigation or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective at a reasonable-assurance level; no material change in internal control was reported during the quarter.
Key facts for investors to verify
- EvinceMed’s final purchase-price allocation, integration progress and expected financial contribution.
- Whether revenue growth and improved gross margin persist, and how customer concentration affects results.
- Cash-flow sustainability, including the contribution from receivables collections and changes in working capital.
- The trajectory of operating costs and the impact of stock-based compensation on losses and future share dilution.
- Progress against management’s qualitative 2022 outlook; the filing provides no numerical annual revenue or earnings guidance.